$2.31 billion is the projected 2036 value for the genome engineering organ transplant market, up from $1.10 billion in 2026, implying a 7.7% annual growth rate.
7.7% growth is tied to regulatory progress for engineered donor organs and broader clinical evaluation, but commercial uptake still depends on transplant centers building governed pathways for compatibility testing and long-term recipient monitoring.
31.1% of the 2026 technology segment is expected to come from CRISPR-Cas9, while kidney programs lead organ demand with a 33.2% share and xenotransplantation leads applications at 34.0%.
44.0% of 2026 end-user spending is projected to sit with transplant centers, reflecting their control over surgery, patient selection, adverse-event management and follow-up.
9.4% CAGR makes Japan the fastest-growing profiled market through 2036, ahead of the UK at 8.3% and the US at 7.5%, as organ shortages and local clinical readiness shape adoption.
As biotechs rush to commercialize xenotransplantation, who will ultimately control the pricing and global availability of these engineered animal organs?
Will CRISPR-edited pig organs permanently solve the transplant crisis, or merely introduce unforeseen zoonotic diseases into the human population?
Beyond genetic edits, can experimental thymic cell therapies truly trick the human immune system into accepting animal organs forever?
From Compassionate Use to Clinical Trials: The Rapid Rise of Gene-Edited Pig Organ Transplants and Their Global Implications
Overview
This report traces the rapid progress of xenotransplantation, beginning with the first gene-edited pig-to-human kidney transplant in 2021 and moving to multiple landmark surgeries in living patients between 2024 and 2026. Driven by a severe global organ shortage, the field has shifted from single-patient emergency procedures to structured clinical trials, such as the EXPAND trial evaluating 10-gene-edited pig kidneys. Japan and other countries are adapting regulations and leveraging international data to accelerate local trials. The adoption of CRISPR-Cas9 technology enables precise, multi-gene editing, making pig organs more compatible with humans and supporting the transition toward routine clinical use.